Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin
ConclusionsIn AGC patients receiving the first-line therapy, ETS and DpR might be predictors for PFS and OS.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Study